3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl-, hydrochloride (1:2)

Request For Quotation
3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl-, hydrochloride (1:2) Suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: 13564774135
Email: marketing@targetmol.com
Products Intro: Product Name:3,6-DMAD dihydrochloride
CAS:2226511-77-7
Package:25mg;1520USD|50mg;1980USD|100mg;2500USD
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Products Intro: Product Name:3,6-DMAD dihydrochloride
CAS:2226511-77-7
Package:25mg/RMB 10600;50mg/RMB 13800;100mg/RMB 17500

3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl-, hydrochloride (1:2) manufacturers
3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl-, hydrochloride (1:2) Basic information
Product Name:3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl-, hydrochloride (1:2)
Synonyms:3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl-, hydrochloride (1:2);3,6-DMAD dihydrochloride
CAS:2226511-77-7
MF:C22H32ClN5
MW:401.98
EINECS:
Product Categories:
Mol File:2226511-77-7.mol
3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl-, hydrochloride (1:2) Structure
3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl-, hydrochloride (1:2) Chemical Properties
Safety Information
MSDS Information
3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl-, hydrochloride (1:2) Usage And Synthesis
Uses3,6-DMAD dihydrochloride, an acridine derivative, is a potent IRE1α-XBP1s pathway inhibitor. 3,6-DMAD dihydrochloride promotes IL-6 secretion via the IRE1α-XBP1s pathway. 3,6-DMAD dihydrochloride inhibits IRE1α oligomerization and endoribonuclease (RNase) activity. 3,6-DMAD dihydrochloride can be used for research of cancer[1][2].
in vivo

3,6-DMAD dihydrochloride (10 mg/kg; i.p.; three times every 12 hours, for 84 hours; NOD Scid mice with RPMI 8226 xenograft) has inhibition of XBP1 splicing in vivo[1].
3,6-DMAD dihydrochloride (10 mg/kg; 24 h; i.p.; every 48 hours, for 12 days; NOD Scid mice with RPMI 8226 xenograft) suppresses multiple myeloma xenograft growth in vivo[1].

Animal Model:NOD Scid mice (4-6 weeks) with RPMI 8226 xenograft[1]
Dosage:10 mg/kg
Administration:Intraperitoneal injection; three times every 12 hours, for 84 hours
Result:Inhibited XBP1-luciferase activity in NOD Scid mice with RPMI 8226 xenograft.
Animal Model:NOD Scid mice (4-6 weeks) with RPMI 8226 xenograft[1]
Dosage:10 mg/kg
Administration:Intraperitoneal injection; every 48 hours, for 12 days
Result:Inhibited tumor growth in NOD Scid mice with RPMI 8226 xenograft.
References[1] Jiang D, et, al. Acridine Derivatives as Inhibitors of the IRE1α-XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma. Mol Cancer Ther. 2016 Sep;15(9):2055-65. DOI:10.1158/1535-7163.MCT-15-1023
[2] De SY, et, al. SHP-2 specific deletion in macrophages accelerates pathological cardiac hypertrophy through promoting IRE1α-XBP1s pathway regulated by IL-6 secretion. Research Article. 2022 May 3.
3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl-, hydrochloride (1:2) Preparation Products And Raw materials
Tag:3,6,9-Acridinetriamine, N9-[3-(dimethylamino)propyl]-N3,N3,N6,N6-tetramethyl-, hydrochloride (1:2)(2226511-77-7) Related Product Information
3,6-DMAD hydrochloride IRE1 Protein, HUMAN (SF9)